Indian stocks: Visit www.stage2stocks.com →

Trevi Therapeutics, Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, Trevi Therapeutics is in Stage 3, the topping phase, now in week 5 (since Sep 18, 2026). It closed at $12.94, 33.6% below its 52-week high and below its 200-day average, which is rising.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibro… More about the company

$12.94
+1.33% today
$1.8B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is TRVI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 23w
S2 16w
S2 30w
S2 27w
S2 23w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 2w → S4 23w → S1 5w → S2 10w → S3 9w → S2 16w → S3 4w → S2 30w → S3 1w → S2 27w → S3 10w → S2 23w → S3 5w current
Total tracked: 165 weeks across 13 stage runs.

TRVI among Biotechnology131st of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…131TRVIStage 3 · wk 571−10.5%
vs 52W High
-33.6%
$9.99 lo$19.50 hi
33.6% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 5
1w13w26w
Week 5, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-9.4%
200 DMA: $14.29 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.57x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-10.5%
3M
-26.2%
6M
-8.8%
YTD
+8.8%
1Y
+21.5%
Scan Membership
Breakout Watch
Latest: 2024-12-23
7 appearances in last 60 days. First seen: 2020-07-07.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 5 · Vol 0.57x
2026-10-21S3
Wk 5 · Vol 1.25x
2026-10-20S3
Wk 5 · Vol 0.90x
2026-10-19S3
Wk 5 · Vol 0.78x
2026-10-16S3
Wk 5 · Vol 1.34x
2026-10-15S3
Wk 4 · Vol 0.85x
2026-10-14S3
Wk 4 · Vol 1.51x
2026-10-13S3
Wk 4 · Vol 0.79x
2026-10-12S3
Wk 4 · Vol 2.47x
2026-10-09S3
Wk 4 · Vol 2.70x
2026-10-08S3
Wk 3 · Vol 3.60x
2026-10-07S3
Wk 3 · Vol 3.18x
Moving averages & range
50 DMA
$15.32
200 DMA
$14.29
52W High
$19.50
52W Low
$9.99
5D Low
$11.88
Resistance levels (recent highs)
20d High
$14.42
60d High
$18.84
120d High
$19.50
250d High
$19.50
Next resistance
+11.4%
to 20d High
ROE
-19.7%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 5.7

Trevi Therapeutics: quick answers

What stage is Trevi Therapeutics in?

As of Oct 22, 2026, Trevi Therapeutics (TRVI) is in Stage 3, the topping phase. It entered Stage 3 on Sep 18, 2026 and is in week 5. What the four stages mean

Is Trevi Therapeutics in an uptrend?

Its uptrend has stalled. Trevi Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 9.4% below its 200-day average, which is rising.

How far is Trevi Therapeutics from its 52-week high?

Trevi Therapeutics closed at $12.94 on Oct 22, 2026, 33.6% below its 52-week high of $19.50. Its 52-week low is $9.99.

How has Trevi Therapeutics performed over the past year?

As of Oct 22, 2026, Trevi Therapeutics is up 21.5% over the past year and up 8.8% so far in 2026.

Which sector and industry is Trevi Therapeutics in?

Trevi Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.